Examining the Relationship Between Metformin Use and Prostate Cancer Outcomes

Tuesday, 16 July 2024, 16:14

This meta-analysis investigates the effects of metformin on prostate cancer patients, focusing on incidence, recurrence, and mortality. Results suggest that metformin may lower the risk of developing prostate cancer, particularly in cohorts from Asia and Europe. While metformin showed a protective effect on incidence, its impact on recurrence and mortality was not statistically significant. Furthermore, the duration of metformin use was found to be positively correlated with its protective effects, emphasizing its potential as a preventive measure.

Nature — Examining the Relationship Between Metformin Use and Prostate Cancer Outcomes

Metformin's Impact on Prostate Cancer: Insights from Real-World Studies

This meta-analysis examines the effects of metformin on prostate cancer patients, focusing on key outcomes such as incidence, recurrence, and mortality.

Key Findings:

Lower Incidence: Metformin was associated with a reduced risk of developing prostate cancer (RR: 0.82).
Recurrence Reduction: While metformin showed potential in reducing recurrence, the results were inconclusive (RR: 0.97).
No Effect on Mortality: Metformin use did not impact prostate cancer mortality rates (RR: 0.94).

The study emphasizes a positive correlation between the duration of metformin use and its protective effects against prostate cancer incidence.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.